• Taysha Gene Therapies’ third-quarter 2026 net loss widened 20% year over year to $39.1 million.
• General and administrative expenses jumped 58% to $13.1 million, while research and development expenses rose 12% to $28.8 million.
• Cash and cash equivalents totaled $422.8 million at September 30, with funding expected to support planned operations into the second half of 2028.
• The TSHA-102 commercial-scale manufacturing validation campaign met predefined product specifications and comparability criteria, supporting a potential BLA submission.
• REVEAL pivotal trial six-month interim data and FDA feedback on the TSHA-102 BLA submission pathway are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456974), on November 12, 2026, and is solely responsible for the information contained therein.